Facebook Twitter YouTube Google Plus

Mesothelin: A New Target for Immunotherapy

In this interview with Mary Hesdorffer, the Meso Foundation's executive director and expert nurse practitioner, Dr. Raffit Hassan, Senior Investigator and Chief of the Solid Tumor Immunotherapy Section in the Laboratory of Molecular Biology at the National Cancer Institute (NCI) and former Chair of the Meso Foundation’s Science Advisory Board, discussed his research into mesothelin and development of clinical trials using mesothelin as a target for epithelial malignant mesothelioma, providing both pleural and peritoneal mesothelioma patients with the potential of much-needed new treatment options.

A 2011 recipient of the Meso Foundation’s Pioneer Award for breakthroughs in mesothelioma research, Dr. Hassan has focused his own trials on targeting mesothelin as a potential treatment of patients with mesothelioma. Dr. Hassan’s research began in the NCI laboratory and continues to this day.

Listen to more Meet the Mesothelioma Experts podcasts